Predict your next investment

Singleron company logo
HEALTHCARE | Biotechnology
singleronbio.com

See what CB Insights has to offer

Founded Year

2018

Stage

Series A - III | Alive

Total Raised

$74.59M

Last Raised

$30M | 7 mos ago

About Singleron

Xingeyuan is a developer of gene sequencing technology, focusing on massive and single-cell multi-omics analysis for drug development, scientific research, and genomics industries. The company is developing a series of molecular diagnostic products and automation devices that can meet clinical applications.

Singleron Headquarter Location

Jiyin Building, 10/F 211 Pubin Rd, Jiangbei New District

Nanjing, Jiangsu,

China

+86 025-58165529

Latest Singleron News

Sherpa Healthcare Partners closes oversubscribed Fund II

Jul 21, 2021

Submitted21/07/2021 - 2:47pmSherpa Healthcare Partners has held the closing of its oversubscribed Sherpa Healthcare Fund II.The fund focuses on early- to growth-stage investments in China healthcare sector to cover companies in biotech/biopharma, medical devices/diagnostics, and medical services. The Fund's LPs include public pension plans, sovereign wealth funds, foundations, family offices, funds of funds, asset management companies, and other institutional investors.Outstanding portfolio companies of Sherpa Healthcare Funds include Cytek Biosciences, New Horizon Health, Singleron, Epimab, NanoVision, Belief Biomed, Stroke Care, Blissbio, VisionX, Visen, and many more.Kirkland & Ellis advised Sherpa Healthcare Partners.Like this article? Sign up to our free newsletterRelated TopicsFundsLaunches & Fundraising - Access Over 250K+ Industry Headlines, Posts and Updates ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY.CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN.PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS.THIS IS NOT A SOLICITATION FOR INVESTMENT.THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY.IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES.ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM.PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT. ALPHAMAVEN

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Singleron

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Singleron is included in 6 Expert Collections, including Genomics.

G

Genomics

823 items

Companies involved in the capture, sequencing, and/or analysis of genetic data

C

China Digital Health Collection

467 items

M

Medical Devices

8,341 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

B

Biopharmaceuticals

5,731 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

O

Omics

975 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

D

Digital Health

9,303 items

Companies that use or incorporate digital technology into their health/wellness product & service offerings. Only those that have raised funding after 01/01/2010

Singleron Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Singleron Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.